This trial is testing if adding chemotherapy to the standard treatment can lower the number of cancer cells in the blood.
- Non-Small Cell Lung Cancer
1 Primary · 4 Secondary · Reporting Duration: 2 years
Side Effects for
2 Treatment Groups
Cohort 1 minimal residual disease positive (MRD+)
1 of 2
Cohort 2 minimal residual disease negative (MRD )
1 of 2
48 Total Participants · 2 Treatment Groups
Primary Treatment: Durvalumab · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 17 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are patients presently being enrolled in this medical study?
"Yes, the trial is still recruiting according to the information on clinicaltrials.gov. This particular study was posted on 8/25/2021 and was updated 8/31/2021. They are looking for 48 patients from 1 site." - Anonymous Online Contributor
Is this a large-scale study or a smaller one?
"Yes, this is an ongoing trial that is currently seeking participants. According to the information available on clinicaltrials.gov, the trial was first posted on 8/25/2021, and the most recent update was on 8/31/2021. They are looking for 48 participants total, at 1 site." - Anonymous Online Contributor
For what purpose is Durvalumab most often prescribed?
"Durvalumab can be used as a therapeutic intervention for patients suffering from malignant neoplasms, locally advanced nonsquamous non-small cell lung cancer, and conditioning regimens for allogeneic stem cell transplantation therapy." - Anonymous Online Contributor
Is Durvalumab known to have any negative health effects?
"Power has given Durvalumab a safety score of 3. This is based on the fact that it is a Phase 3 trial, which suggests that not only is there some evidence of its efficacy, but also that there is repeated evidence of its safety." - Anonymous Online Contributor